This website (the “Site”) is operated by Informa Connect, a trading division of the Informa Group. The parent company of the Informa Group is Informa PLC. Informa Connect (“Informa Connect”, “we” or ...

In its Q4 earnings call to investors on February 25, vaccine developer Vaxcyte expressed optimism about its VAX-31 invasive pneumococcal disease (IPD) vaccine program and discussed the company’s ...

Isolere Bio is on a mission to transform biomanufacturing and tackle the traditional limitations in downstream processing with its novel IsoTag reagents. This first-of-its-kind technology is based on ...

At the JP Morgan Healthcare Conference, while addressing the state of the company in 2025, experts from Gilead Sciences touted the company’s manufacturing infrastructure as one of its key advantages ...

Announced in 2021, the facility, named Modulus, is expected to be fully operational by 2026 and will create about 200 jobs locally. Modulus is Sanofi’s first "EVolutive vaccine facility (EVF)" outside ...

Biologics have revolutionized the medical landscape with their targeted mechanisms of action and potential for treating a wide array of indications. As the global population grapples with an ...

Ensuring regulatory compliance and maintaining high-quality standards is fundamental in the pharmaceutical industry. However, the conventional approach of computer system validation (CSV) is proving ...

Filter integrity is a fundamental element of sterility assurance during production of biopharmaceutical and vaccine products. Integrity test results are a key foundation for drug lot release, so any ...

The firms will co-commercialize the products globally, except for MK-6070 in Japan where Merck (known as MSD outside of the US and Canada) will retain the exclusive rights. Merck will also be solely ...

In this informative white paper, WuXi Biologics delves into how WuXi Biologics addressed the critical need for speed in moving biologics from DNA to Investigational New Drug (IND) application ...

Sanofi will build a €1 billion ($1.1 billion) mAb production facility in Vitry-sur-Seine, while it invests €100 million to bolster capacity at its Le Trait site in Normandy and invests €10 million at ...

In 2021, Fujifilm began constructing a biomanufacturing site in Holly Springs, North Carolina at a cost of ¥200 billion (then $2 billion, now $1.3 billion) for its contract development manufacturing ...